ИСТИНА

Matrix metalloproteinases (MMPs) are cation-depended enzymes involved in the catabolic degradation of matrix proteins, playing an important function in the oncogenesis. They are validated targets in drug discovery and their modulators are already listed among several clinical candidates.[2] Despite the initial efforts in finding MMP modulators for cancer, most of them resulted in phase III failure due to their lack of specificity. That is why it is crucial addressing the selectivity pattern since the very beginning. Based on the MMP-2, MMP-13 and MMP-8 role in cancer pathology, it clearly emerges the advantages that a modulator with the correct selective pattern versus these three proteases could be an effective tool against cancer.